Ali Alamdar Shah Syed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Alamdar Shah Syed has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Lin He
Bio‐X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science Shanghai Jiao Tong University Shanghai China
1 shared publication- Lin He
Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai 200030, China
1 shared publication Shahid Mahmood
Bio‐X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science Shanghai Jiao Tong University Shanghai China
1 shared publicationYongyong Shi
Bio‐X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Collaborative Innovation Center for Brain Science Shanghai Jiao Tong University Shanghai China
1 shared publication- Yongyong Shi
Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China
1 shared publication
Latest Publications
- 9 September 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (4) , 896-905
Elevated levels of IL‐18 associated with schizophrenia and first episode psychosis: A systematic review and meta‐analysis
Aim: To determine whether interleukin 18 (IL‐18) is elevated in the blood of schizophrenia (SCZ) and first episode psychosis patients, as well as investigate whether this potential relationship is causal.Method: We conducted a systematic review and meta‐analysis of IL‐18 levels in the blood of SCZ patients, comprising of both chronic and first episode psychosis (FEP) cohorts. To investigate causality, we undertook the two‐sample Mendelian randomization (MR) study.Results: A total of eight studies were included in our meta‐analysis, our results did indeed show an association between elevated levels of IL‐18 and SCZ compared to healthy controls (Z = 3.50, P = .0005). This association remained significant in subsequent subgroup analyses for chronic (Z = 3.15, P = .002) and achieved borderline significance in FEP (Z = 1.93, P = .05) SCZ. Our MR analysis failed to detect any causal relationship between IL‐18 levels and SCZ.Conclusion: The results of our study demonstrate that even though IL‐18 levels are elevated in SCZ patients, IL‐18 levels do not seem to cause of the disorder itself. Our findings suggest that IL‐18 may have utility as a biomarker of SCZ and aid in research into the early intervention of the disease.
- 9 September 2020
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 15 (4) , 896-905
Elevated levels of IL‐18 associated with schizophrenia and first episode psychosis: A systematic review and meta‐analysis
Aim: To determine whether interleukin 18 (IL‐18) is elevated in the blood of schizophrenia (SCZ) and first episode psychosis patients, as well as investigate whether this potential relationship is causal.Method: We conducted a systematic review and meta‐analysis of IL‐18 levels in the blood of SCZ patients, comprising of both chronic and first episode psychosis (FEP) cohorts. To investigate causality, we undertook the two‐sample Mendelian randomization (MR) study.Results: A total of eight studies were included in our meta‐analysis, our results did indeed show an association between elevated levels of IL‐18 and SCZ compared to healthy controls (Z = 3.50, P = .0005). This association remained significant in subsequent subgroup analyses for chronic (Z = 3.15, P = .002) and achieved borderline significance in FEP (Z = 1.93, P = .05) SCZ. Our MR analysis failed to detect any causal relationship between IL‐18 levels and SCZ.Conclusion: The results of our study demonstrate that even though IL‐18 levels are elevated in SCZ patients, IL‐18 levels do not seem to cause of the disorder itself. Our findings suggest that IL‐18 may have utility as a biomarker of SCZ and aid in research into the early intervention of the disease.
- Open Access
The Potential Effect of Aberrant Testosterone Levels on Common Diseases: A Mendelian Randomization Study
Testosterone has historically been linked to sexual dysfunction; however, it has recently been shown to affect other physical and mental attributes. We attempted to determine whether changes in serum testosterone could play a role in chronic or degenerative diseases. We used two separate genetic instruments comprising of variants from JMJD1C and SHBG regions and conducted a two-sample Mendelian randomization for type II diabetes (T2D), gout, rheumatoid arthritis (RA), schizophrenia, bipolar disorder, Alzheimer’s disease and depression. For the JMJD1C locus, one unit increase in log transformed testosterone was significantly associated with RA (OR = 1.69, p = 0.02), gout (OR = 0.469, p = 0.001) and T2D (OR = 0.769, p = 0.048). Similarly, one unit increase in log transformed testosterone using variants from the SHBG locus was associated with depression (OR = 1.02, p = 0.001), RA (OR = 1.32, p < 0.001) and T2D (OR = 0.88, p = 0.003). Our results show that low levels of serum testosterone levels may cause gout and T2D, while higher than normal levels of testosterone may result in RA and depression. Our findings suggest that fluctuations in testosterone levels may have severe consequences that warrant further investigation.
Open AccessThe Potential Effect of Aberrant Testosterone Levels on Common Diseases: A Mendelian Randomization Study
Testosterone has historically been linked to sexual dysfunction; however, it has recently been shown to affect other physical and mental attributes. We attempted to determine whether changes in serum testosterone could play a role in chronic or degenerative diseases. We used two separate genetic instruments comprising of variants from JMJD1C and SHBG regions and conducted a two-sample Mendelian randomization for type II diabetes (T2D), gout, rheumatoid arthritis (RA), schizophrenia, bipolar disorder, Alzheimer’s disease and depression. For the JMJD1C locus, one unit increase in log transformed testosterone was significantly associated with RA (OR = 1.69, p = 0.02), gout (OR = 0.469, p = 0.001) and T2D (OR = 0.769, p = 0.048). Similarly, one unit increase in log transformed testosterone using variants from the SHBG locus was associated with depression (OR = 1.02, p = 0.001), RA (OR = 1.32, p < 0.001) and T2D (OR = 0.88, p = 0.003). Our results show that low levels of serum testosterone levels may cause gout and T2D, while higher than normal levels of testosterone may result in RA and depression. Our findings suggest that fluctuations in testosterone levels may have severe consequences that warrant further investigation.